Paul J. Shaughnessy, MD

Articles

Clinical Trials and Real-World Data on Brexu-Cel

January 30th 2025

Panelists discuss how the dosing and lymphodepletion regimens of brexucabtagene autoleucel (brexu-cel), tisagenlecleucel (tisa-cel), and obecabtagene autoleucel (obe-cel) differ, with insights into obe-cel’s double infusion approach, as well as a deeper dive into the ZUMA-3 trial’s design and data updates with brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Introduction to CAR T-Cell Therapies in R/R ALL

January 30th 2025

Panelists discuss how the recent FDA approval of obecabtagene autoleucel (obe-cel) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) adds to the existing chimeric antigen receptor (CAR) T-cell therapies, with a focus on the differences in their mechanisms, structures, and FDA indications.

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

November 28th 2024

Dr Shaughnessy discusses the significance of the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Dr. Shaughnessy on the Potential of the FELIX Trial to Address Unmet Needs in B-ALL

December 23rd 2022

Paul J. Shaughnessy, MD, discusses the potential of the phase 1/2 FELIX trial to address unmet needs in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Shaughnessy on Addressing Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

Dr. Shaughnessy on Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 4th 2020

Paul J. Shaughnessy, MD, discusses challenges with CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Dr. Shaughnessy on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

July 30th 2020

Paul J. Shaughnessy, MD, discusses the promising future of CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Dr. Shaughnessy on the Emergence of CAR T-Cell Therapy in Hematologic Malignancies

July 21st 2020

Paul J. Shaughnessy, MD, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

Dr. Shaughnessy on Available CAR T-Cell Therapies in R/R Hematologic Malignancies

July 17th 2020

Paul J. Shaughnessy, MD, discusses the available CAR T-cell therapies for relapsed/refractory hematologic malignancies.

Dr. Shaughnessy Discusses Unanswered Questions in DLBCL

April 4th 2019

Paul J. Shaughnessy, MD, medical director of adult blood and marrow transplant at the Texas Transplant Institute, discusses unanswered questions in the field of diffuse large B-cell lymphoma (DLBCL).

Dr. Shaughnessy Discusses Stem Cell Mobilization in Lymphomas

February 25th 2019

Paul J. Shaughnessy, MD, discusses stem cell mobilization in patients with lymphomas.